Promise Bio

Promise Bio Overview

Promise Bio, a recent spin-out from the Weizmann Institute, is the first company to harness post-translational modifications (PTM) and artificial intelligence to reveal unique biological insights that are otherwise overlooked. Understanding immune-mediated diseases requires uncovering intricate proteomic patterns, and PTMs are the key to capturing the regulated part of the proteome. The PROMISE platform uses proprietary Comprehensive PTM Profiling to detect up to 45 PTM types simultaneously, allowing maximal knowledge extraction from biological data and offering a unique approach to identifying functional biomarkers from diverse biological samples (PBMCs, tissue biopsies, urine). With a proprietary technology recently published in Nature Biotechnology, we partner with pharmaceutical companies to unleash the potential of their data-driven discovery, by looking at biology where it matters the most for complex chronic diseases.

Cumulative Funding Raised Over Time ($)

Latest News

Dec 16, 2024 · www.calcalistech.com

growth-positive

The Israeli startup's computational platform uses epiproteomics and AI to predict patient treatment responses and support drug research and development.

Promise Bio, a startup focused on treating immune-mediated diseases with precision medicine, has emerged from stealth with an $8.3 million Seed investment. The funding round was led by Awz Ventures and included contributions from AstraZeneca, Pfizer, and the Israel Innovation Authority. This investment will accelerate the development of Promise Bios computational platform, which leverages epiproteomics and AI to predict patient treatment responses and support drug research. The platform, based on research by Dr. Assaf Kacen at the Weizmann Institute of Science, aims to improve the effectiveness of autoimmune disease treatments by focusing on protein modifications. The company seeks to eliminate the trial-and-error approach in current treatments, which only achieve significant remission in 30-40% of patients.

Investment

Dec 16, 2024 · www.prnewswire.com

growth-positive

/PRNewswire/ -- Promise Bio, a startup transforming immune-mediated disease treatment with advanced precision medicine solutions, today announced its emergence...

Promise Bio, a startup focused on precision medicine for immune-mediated diseases, has emerged from stealth with an $8.3 million seed investment. The funding, led by Awz Ventures and supported by AION Labs, AstraZeneca, and Pfizer, will accelerate the development of Promise Bios platform that integrates epiproteomics and AI to predict patient treatment responses. The company aims to transform treatment approaches by focusing on protein modifications and leveraging machine learning. Strategic partnerships with leading biopharmaceutical companies provide financial backing and industry expertise, positioning Promise Bio to advance precision medicine solutions and build the worlds largest PTM database.

InvestmentPartners

Funding

Team Members

1

Employees: 11-50

Web & Social Links

Locations

Tel Aviv-Yafo, Israel

Photos & Videos

No files yet

Promise Bio Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info